Role of cholesterol in the regulation of growth plate chondrogenesis and longitudinal bone growth.
Inborn errors of cholesterol synthesis are associated with multiple systemic abnormalities, including skeletal malformations. The regulatory role of cholesterol during embryogenesis appears to be mediated by Shh, a signaling molecule in which activity depends on molecular events involving cholesterol. Based on this evidence, we hypothesized that cholesterol, by modifying the activity of Ihh (another of the Hedgehog family proteins) in the growth plate, regulates longitudinal bone growth. To test this hypothesis, we treated rats with AY 9944, an inhibitor of the final reaction of cholesterol synthesis. After 3 weeks, AY 9944 reduced the cumulative growth, tibial growth, and the tibial growth plate height of the rats. To determine whether cholesterol deficiency affects bone growth directly at the growth plate, we then cultured fetal rat metatarsal bones in the presence of AY 9944. After 4 days, AY 9944 suppressed metatarsal growth and growth plate chondrocyte proliferation and hypertrophy. The inhibitory effect on chondrocyte hypertrophy was confirmed by the AY 9944-mediated decreased expression of collagen X. Lastly, AY 9944 decreased the expression of Ihh in the metatarsal growth plate. We conclude that reduced cholesterol synthesis in the growth plate, possibly by altering the normal activity of Ihh, results in suppressed longitudinal bone growth and growth plate chondrogenesis.
Wu
Shufang
S
Section of Endocrinology and Diabetes, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, Pennsylvania 19134, USA.
De Luca
Francesco
F
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D001846:Bone Development / Q000187:drug effects / Q000502:physiology*; D002784:Cholesterol / Q000096:biosynthesis / Q000502:physiology*; D020219:Chondrogenesis / Q000187:drug effects / Q000502:physiology*; D006132:Growth Plate / Q000187:drug effects / Q000254:growth & development*; D053823:Hedgehog Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D066298:In Vitro Techniques; D008148:Lovastatin / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015534:Trans-Activators / Q000502:physiology; D001371:trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride / Q000494:pharmacology
D000924:Anticholesteremic Agents; D053823:Hedgehog Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D015534:Trans-Activators; D001371:trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; D002784:Cholesterol; D008148:Lovastatin